Cardiac electronic implantable devices in the treatment of heart failure

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Research

Background:

• Heart failure prevalence is rising globally due to aging populations, leading to high morbidity and mortality.
• Electrical conduction disturbances, such as delayed left ventricular activation and mechanical dyssynchrony, contribute significantly to heart failure complications and sudden cardiac death.
• Despite advances in pharmacologic therapy, many heart failure patients on optimal medical treatment experience persistent, debilitating symptoms.

Purpose of the Study:

• To review the current evidence on implantable cardioverter-defibrillators (ICDs) for reducing sudden cardiac death in advanced systolic dysfunction.
• To examine the efficacy of cardiac resynchronisation therapy (CRT) in enhancing ventricular performance, and reducing mortality and morbidity in heart failure patients.
• To assess the role of device therapy as an established treatment for heart failure patients receiving standard medical care.

Main Methods:

• Review of current scientific literature and clinical trial data.
• Analysis of evidence regarding the effectiveness of ICDs in preventing sudden cardiac death.
• Evaluation of studies on CRT's impact on ventricular function, patient survival, and quality of life.

Main Results:

• ICDs are effective in reducing sudden cardiac death in specific heart failure populations.
• CRT demonstrates significant benefits in improving cardiac performance and reducing adverse outcomes.
• Device therapy, including ICDs and CRT, offers a valuable addition to medical management for selected heart failure patients.

Conclusions:

• Implantable cardioverter-defibrillators play a crucial role in mitigating sudden cardiac death risk in patients with advanced systolic dysfunction.
• Cardiac resynchronisation therapy is a vital therapeutic option for improving heart failure management, enhancing ventricular function, and reducing mortality.
• Device therapy represents an established and effective strategy for managing heart failure, complementing pharmacologic treatments and improving patient prognosis.